Rationale: Despite significant advances in knowledge of the genetic architecture of asthma, specific contributors to the variability in the burden between populations remain uncovered.
Asthma is a common chronic disease of the airways characterized by recurrent episodes of wheezing, coughing, and shortness of breath. In the United States, it is estimated that at least 22.9 million people suffer from the condition, with significant ancestral disparities regarding prevalence, severity, and treatment outcomes across populations (1, 2) .
Compared with European Americans (EAs), African Americans (AAs) have higher lifetime prevalence of asthma (14.09% vs. 12.41%) (3), higher morbidity, with twice the hospitalization and 1.5 times the intensive care unit admission or intubation (4) , and 7.6 times the death rate (5) .
Asthma is highly heritable (6) . It is well established that genetic risk factors vary within and between diverse populations (7, 8) . Over the past decade, several population-specific and shared genetic risk factors have been identified through genome-wide association studies (GWAS). These loci include the IL1R1/IL18R1 region at 2q12.1 (9, 10) , the cytokine cluster at 5q31.1 (11, 12) , and the innate immune mediator TSLP (5q22.1) (10, 13, 14) ; the HLA region at 6p21. 32-33 (11-13) , IL33 at 9p24.4 (9, 10, 15) , SMAD3 at 15q22.33 (9, 15) , 17q21-12 (ORMDL3/GSMDB) (16, 17) , DENND1B (1q31) (18) , and CDHR3 (7q22.3) (19) . However, despite the significant advances in knowledge of the genetic architecture of asthma, specific contributors to the observed variability in the burden of asthma between populations remain to be discovered.
In this study, we conducted a GWAS in patients with asthma of EA and AA descent recruited from the Electronic Medical Records and Genomics (eMERGE) network, using an algorithm based on electronic medical record (EMR) mining. The eMERGE network is a National Human Genome Research Institute-funded consortium that comprises a diverse cohort of more than 57,000 participants linked to EMRs for phenotype mining from nine participating sites in the United States (20) . The large number of study participants and diversity of the eMERGE sites provide an excellent means for investigating the genetic architecture of asthma across populations of different ancestry.
Methods Study Subjects and Definition of the Asthma Phenotype
Pediatric asthma cases and control subjects from The Children's Hospital of Philadelphia (CHOP) were selected from the biorepository at the Center for Applied Genomics, which has a collection of more than 160,000 samples including more than 90,000 internal pediatric samples genotyped using standard genome-wide arrays and linked to subjects' EMRs. All subjects have consented to analyses and EMR mining from the full longitudinal record, which has a mean duration greater than 5.5 years per subject. Mean age of these subjects is 11 years and 47% are of EA ancestry, 43% are AAs, and 10% from other ancestry groups (20) .
The adult asthma cohort was collected from seven sites from the eMERGE Network (see Table E1 in the online supplement). Characteristics of the sample collected at each site can be found in detail (20) . For all sites except Mount Sinai, EA ancestry represented more than 80% of the subjects and the mean age of cases was greater than 48 years.
The project was approved by the institutional review boards at CHOP and each of the eMERGE participating sites. Written informed consent was obtained from each participant in accordance with institutional requirements and the Declaration of Helsinki Principles.
Asthma cases and control subjects were identified using an EMR-based algorithm developed at CHOP, similar to Pacheco and colleagues (21) , and validated and implemented by the seven eMERGE sites.
The inclusion criteria for cases included being greater than or equal to 4 years and either having received greater than or equal to one prescriptions of asthma-related medications (see Table E2 ) and diagnosed with greater than or equal to one of International Classification of Diseases, 9th Edition (ICD9) codes 493.00-493.92 in greater than or equal to two in-person visits, on separate calendar days; or having greater than or equal to three in-person visits in any 12-month period, on separate calendar days, with affirmative mentions of "wheezing" or "asthma" in EMR notes. The algorithm was also designed to identify subjects with allergic asthma, defined as individuals having either ICD9 codes for extrinsic asthma (493.00, 493.01, or 493.02), or greater than or equal to two ICD9 codes related to allergies (see Table E3 ) on separate calendar days. Exclusion criteria used for cases included having any ICD9 codes related to respiratory conditions or organ transplantation (see Table E4 ).
Subjects were selected as controls if they had no ICD9 code for asthma, no history of asthma medications, no positive confirmation of "wheezing" or "asthma" in the patient charts, and no exclusionary ICD9 codes (see Table E4 ).
The validity of the algorithm was initially assessed on a sample of 100 randomly selected EMRs at CHOP revealing some modification requirements: several prescriptions for medications not included encoding the endothelial tyrosine kinase, and PTGES, both of which have been linked with asthma in in vitro and in vivo models. However, this is the first report of genetic variants in these genes contributing to the susceptibility to asthma. The advantage of using a phenotyping algorithm over traditional crosssectional studies includes a more accurate and objective definition of the asthma diagnosis based on International Classification of Diseases, 9th Edition codes and the prescription of asthma medications, with more comprehensive information on the phenotype. This approach has allowed us to uncover novel loci involving pathways previously suspected to contribute to asthma susceptibility and suggests that novel therapies may be developed to more effectively treat the underlying causes of this disease.
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in the initial algorithm were added, and allergy and ICD9 codes 416.xx and 748.5 were added as exclusions for control subjects (see Table E4 ). Consequently, the algorithm was revised to its current form, rerun, and formally validated to generate positive predictive values (PPVs). For the validation, case records were searched for a positive diagnosis of asthma based on physician diagnosis, coughing or wheezing symptoms, and clinical bronchodilator response where available. Similarly, control subjects were reviewed for the absence of clinical evidence of asthma. Evidence of exclusionary ICD9 codes was also assessed.
Internal validation at CHOP consisted of manual chart review of two independent samples: a first sample of 250 randomly selected subjects (76 cases and 174 control subjects) and a second sample of 301 asthma cases. External validation of the phenotyping algorithm included 170 subjects: 100 from Cincinnati Children's Hospital Medical Center (50 cases, 50 control subjects), 20 from Geisinger Clinic (10 cases, 10 control subjects), and 50 from Marshfield (25 cases, 25 control subjects). PPVs with 95% confidence interval were calculated for cases and control subjects at each site.
Genome-Wide Genotyping, Imputation, and Population Stratification Assessment
Genotyping was performed at each eMERGE site using Illumina (San Diego, CA) and Affymetrix (Santa Clara, CA) platforms (see Table E5 ). Imputation of the CHOP cohort was conducted at the Center for Applied Genomics. The eMERGE Coordinating Center (Pennsylvania State University) led the imputation of the adult dataset.
A standard preimputation quality control of the genotyping data was implemented at the individual and single-nucleotide polymorphism (SNP) level using pairwise identity-by-descent values (22) . Cryptic relatedness and duplicated samples were also assessed by pairwise identity-bydescent values and removed. Haplotypes were phased using SHAPEIT version 2 (O. Delaneau, Department of Statistics, University of Oxford, Oxford, UK) (23) . Genome-wide imputation of the pediatric samples was performed with the IMPUTE2 package (B. N. Howie, Department of Statistics, University of Oxford, Oxford, UK) (24) using the cosmopolitan reference panel from the 1,000 Genomes Project, which included 1,092 samples from multiple ancestry groups.
Genotype imputation in the adult cohort was performed as described (25) , using SHAPEIT (23) and IMPUTE2 (24) with the cosmopolitan reference panel from the 1,000 Genomes Project.
Population ancestry was determined by principal component analysis using Eigenstrat 3.0 (A. Price, Department of Genetics, Harvard Medical School, Boston, MA) (26) on the genotyping data in the pediatric samples and the imputed data in the adults (using 35,324 SNPs common to all Illumina and Affymetrix genotyping platforms). Samples were separated into AAs and EAs based on the principal components, which were regenerated for each cohort and included as covariates to control for population stratification in each individual analysis.
Association Analysis
We performed four sets of GWAS analyses in the pediatric and adult datasets, including each ancestry group separately, and we then reanalyzed nominally associated SNPs conditioning on allergy status. For the GWAS, we used SNPTEST (J. Marchini, Department of Statistics, University of Oxford, Oxford, UK) (27) to take into account the genotype uncertainty introduced by the imputation. An additive model was applied to the genotype dosages generated by IMPUTE2 including the proportion of missing data as a covariate. The first 10 principal components and sex were included as covariates in the analysis of the pediatric and the adult cohort and because the imputation at the eMERGE Coordinating Center was conducted for each genotyping platform and site separately, chip type and site were also used as covariates in the adults. Poorly imputed variants ("info" score <0.7), variants with a minor allele frequency less than or equal to 1%, and variants not meeting Hardy-Weinberg equilibrium in control subjects (P , 5 3 10 28 ) were removed from the analysis. Then, METAL (C. J. Willer, Department of Biostatistics, University of Michigan, Ann Arbor, MI) was used for the metaanalyses of the EAs, AAs, and the combined sample, and also in the pediatric and adult data sets, using an inverse variance fixed-effects method, with control for genomic inflation. Additionally, genomic inflation factors for each individual GWAS and metaanalyses were calculated.
A cis-expression quantitative trait locus (eQTL) effect was investigated for all The implementation of the algorithm in the Center for Applied Genomics' biorepository identified 11,784 asthma cases and control subjects. After quality control filtering, 215 samples were removed because of low genotyping call rate and 446 because of cryptic relatedness. Principal component analysis on the remaining 11,569 samples classified 5,680 subjects as AA (49.10%), 5,414 as EA (46.80%), and 474 belonging to other ancestry groups (4.10%). Only individuals in the EA and AA clusters were included in the analysis. The mean age of the final sample (6SD) was 14.02 6 7.7 years, 50.95% of whom were male.
The number of subjects accrued across the eMERGE sites was 11,929, of whom 40.31% were males and with a mean age (6SD) of 64.52 6 17.52 years. Principal component analysis identified 8,970 subjects as EAs (75.19%), 2,025 as AAs (17.31%), and 934 were classified as "other" (7.49%). Only EA and AA clusters were included in the analysis ( Table 1) .
The algorithm was also used to capture the allergy status of the asthma cases. Among the 5,304 pediatric and adult cases, 69.42% had allergic asthma: 79.1% and 51.2% in AA children and adults, respectively, and 84.6% and 42.7% in the EA pediatric and adult cohorts, respectively (Table 1) .
Metaanalyses Reveal Three Novel
We performed GWAS in each of the four cohorts separately and then conducted metaanalyses in the combined sample of 21,644 subjects, in each of the ancestry groups and in the pediatric and adult samples separately (top results with P < 10 26 in Tables E6-E10) .
Genomic inflation factors were 1.015 and 1.056 for the pediatric EAs and AAs, respectively; 1.021 and 1.036 for the adult EAs and AAs, respectively; and 1.015, 1.007, 0.996, 1.013, and 1.000 for the metaanalysis of the combined, EA, AA, pediatric, and adult cohorts, respectively, indicating no population stratification (see Figure E1) .
Two genome-wide significant association signals were identified in the EA-only metaanalysis, consisting of 12 SNPs mapping to two separate loci, including 9p21.2 and 6p21.31 (Table 2, Figure 1 ; see Figure E2 and Table E11 ). The 9p21.2 locus, which included four low-frequency SNPs in LD, spanned three genes: TEK (TEK tyrosine kinase, endothelial), EQTN (equatorin, sperm acrosome associated), and MOB3B (MOB kinase activator 3B). Notably, the significant variants are in LD with a missense variant in TEK (rs682632; Q346P; P = 4.38 3 10
26
). Fine mapping of the region evidenced no eQTL effects in any of the tissues relevant to asthma but effects in other tissues were observed (P , 0.05) (see Table E12 ).
The second significant locus in EAs mapped to 6p21.31 and included eight SNPs in LD (Table 2 ; see Figure E2 ) in the intergenic region between GRM4 (glutamate receptor, metabotropic 4) and HMGA1 (high mobility group AT-hook 1), all variants with slight eQTL effects on HMGA1 in lung (lowest P = 4.7 3 10 23 ) (see Table E12 ).
The AA-only metaanalysis led to the identification of one genome-wide significant SNP in the intronic region of the prostaglandin E synthase gene (PTGES), on chromosome 9 (rs11788591; P = 4.45 3 10 28 ; P value_pediatric = 2.22 3 10 25 ; P value_adult = 2.05 3 10 24 ) (Figure 1 ; see Figure E2 and Table E11 ).
We identified the previously reported SNP rs1837253 in 5q22.1 reaching genomewide significance in the metaanalysis of the combined sample (P = 4.22 3 10 28 ; P value_EA = 1.86 3 10 24 ; P value_AA = 4.80 3 10 24 ) (see Table E11 ). Besides 5q22.1, we also aimed to assess the association of other known asthma SNPs/loci in our sample (see Table E13 ). rs3771166 at 2q12.1, rs2244012 at 5q31.1, rs2381416 at 9p24.1, and all reported SNPs at 17q12-21.1 showed nominal significance in the metaanalysis of the combined sample (P , 5 3 10 23 in all cases). Other loci, such as 11q13.5 (P = 4.73 3 10 25 ) and CLEC16A (P = 7.22 3 10 24 ), also showed association with asthma in our study.
Because asthma is a disease typically occurring during childhood and the pediatric cohort constitutes a more homogeneous population in terms of genetic influence, we also ran metaanalyses in the pediatric and the adult population separately. No significant results were observed in the analysis of the pediatric sample (see Table  E9 ). However, a haplotype in the intronic region of GSDMB was among the top Table E11 .
ORIGINAL ARTICLE associations (P = 3.44 3 10 26 ). In the adultonly analysis, a common intronic variant in PSORS1C1 (psoriasis susceptibility 1 candidate 1) reached genome-wide significance (rs3095318; P = 1.61 3 10 211 ) (see Figure E2 and Table E10 ). The variant is associated with a reduced expression of PSORS1C1 in lung tissue (P = 9.4 3 10 26 ).
Conditioning on Allergy Status Indicates rs72721168 at 9p21.2 Is a Risk Factor for Asthma in EAs Independent of Allergy and Identifies Two Additional Loci
To determine if the observed associations were driven by asthma specifically or more broadly associated with an allergic phenotype we reanalyzed all SNPs that reached nominal significance (P , 5 3 10 23 ) adjusting for allergy status in both EAs (n = 41,835 variants) and AAs (n = 67,774 variants) followed by metaanalyses in the two populations and in the combined sample.
Adjusting the analysis by allergy, the 9p21.2 locus and three low-frequency SNPs on chromosome 10 reached genomewide significance in EAs (Table 3 ; see Figure E2 ). The region includes the genes jumonji domain containing 1C (JMJD1C) and receptor accessory protein 3 (REEP3) at 10q21.3. All three variants are associated with decreased expression of JMJD1C in lung tissue (P = 0.029) in the Genotype-Tissue Expression data.
Discussion
In this study, we present the results from metaanalyses of asthma in individuals of EA and AA ancestry. We replicated the known association of 5q22.1 with asthma and we identified four novel loci at 6p21.31, 9p21.2, and 10q21.3 in EAs and PTGES in AAs.
The strongest association found in this study was with variants at 9p21.1 and asthma in the EAs. The most plausible candidate gene in the region is TEK, which encodes the endothelial tyrosine kinase, commonly referred to as TIE2 and that plays a central role in the regulation of the development and remodeling of the vascular system (30) . TIE2 has been involved in remodeling the airway wall in patients with asthma and models of chronic asthma in mice (31, 32) , evidenced by the correlation between the degree of airway obstruction and expression of TIE2 receptors in the respiratory epithelium in mice; and increased levels of TIE2 ligands, angiopoietins 1 and 2, in the sputum of patients with asthma has been reported (31) . Despite the importance of TIE2 signaling in asthma, to our knowledge this is the first report of genetic variants in TEK contributing to the susceptibility to asthma. Furthermore, this was the only locus where the association remained genome-wide significant after adjusting for allergy status of the asthma cases, indicating that TEK contributes to the risk of asthma independent of allergy status. The second associated locus in the EAs mapped to a 20-kb LD block at 6p21.31 flanked by GRM4 and HGMA1, the latter being expressed in lung and subject to eQTL effects from the associated variants. Notably, a 280-kb LD block in 6p21.32 also showed suggestive association with asthma, independent of 6p21.31, in the EAs and the combined sample. This locus includes the major histocompatibility complex region and has been linked to asthma and related phenotypes in populations of European (11, 14, 16) , Asian (13) , and Latino descent (33) . Interestingly, PSORS1C1 at locus 6p21.33 was associated with asthma in adults. This gene has been previously associated with asthma in Latino population (33) , or chronic obstructive pulmonary disease biomarkers (34) .
Metaanalysis in AAs revealed a novel association of asthma with rs11788591, a common variant in the prostaglandin E synthase gene. Similar to TIE2, the biologic role of prostaglandin E 2 synthase and its product, the inflammatory mediator prostaglandin E 2 , in asthma and other related phenotypes has been extensively investigated (35) (36) (37) (38) (39) . Stumm and colleagues (36) reported a correlation between deficient prostaglandin E 2 synthesis by lung fibroblasts and airway remodeling in mouse models of asthma. Similarly, Reeves and colleagues (38) recently described reduced expression of prostaglandin E 2 synthase by airway epithelial cells of patients with asthma compared with control subjects. Although further confirmation of PTGES as a genetic susceptibility factor for asthma is needed, our findings are supported by the evidence of prostaglandin E 2 -mediated airway remodeling in asthma.
We replicated the previously reported association at TSLP on 5q22.1 across EAs and AAs. TSLP is a TH2 response mediator (40) and has been associated with various atopic traits including asthma in Asian populations (13) , as well as AAs (10), EAs (10, 14) , and Latinos (10). Besides TSLP, two of the most extensively replicated loci across ethnically diverse populations, 17q21-12 and 5q31.1 (16, (41) (42) (43) , also showed suggestive association among the EAs and AAs, respectively. The association at 17q21-12 consisted on a LD block of over 200 kb spanning from PGAP3 to ORMDL3/GSDMB. Interestingly, the metaanalysis in the pediatric sample also yielded a signal in this locus, different from that found in EAs, associated with asthma in both populations and mapping to the intronic region of GSDMB. Together these results suggest that different haplotypes may be associated with asthma in different populations, or that the algorithm used captures different subtypes of asthma depending on the population/age. These population-specific patterns of association have been previously reported by our group (17) and others (10) .
We also aimed to explore whether other SNPs reported in asthma GWAS or metaanalyses replicated in our sample. Most of the well-established asthma susceptibility loci, such as IL1RL1 at 2q12.1, RAD50 at 5q31.1, the HLA region, IL33, or the ORMDL3/GSDMB/GSDMA locus (17q21-12) and others, such as CLEC16A or locus 11q13.5, showed a trend toward significance in our study.
The replication of well-established asthma susceptibility loci along with the high PPVs obtained supports the validity of our algorithm in capturing individuals with asthma using EMR data for investigation of genetic risk factors, as also extensively demonstrated by the eMERGE network (44) . Even though the use of a phenotyping algorithm may not necessarily be more accurate than a prospective study, one of the advantages of using the algorithm for the ascertainment of cases compared with the traditional cross-sectional phenotyping is the accurate and objective definition of the asthma diagnosis based on at least two ICD9 codes and the prescription of specific asthma medications with the possibility of a lengthy follow-up of each individual. However, given the nature of EMR data, there are also limitations, such as the actual need of developing and validating algorithmic approaches to identify study subjects. Data in EMRs can be either structured (ICD9 codes or medications) or unstructured (notes, free text, and so forth), and the latter, which may constitute up to 80% of the value in EMR data (45, 46) often requires the application of natural language processing tools to derive relevant phenotyping elements and thus dedicated expertise. Algorithm sharing is limited by the ability of participating sites to implement these practices and there will always be limits to the capacity to fully capture the richness of clinical notes.
Nevertheless, a benefit of the use of this algorithm is the extensive information collected on secondary phenotypes, such as allergy, which allowed us to investigate whether the observed associations were specific to asthma or more broadly with an allergic phenotype by adjusting for allergy status. When the analysis was adjusted by the allergic status of the cases, additional novel associations were identified. A novel locus in the intergenic region between JMJD1C and REEP3 in 10q21.3 became significant in EAs. JMJD1C encodes a hormone-dependent transcription factor, whose expression has been reported in lymphocytes and lung and has been associated with juvenile idiopathic arthritis (47) . It is noteworthy that except for the significant finding of 9p21.2 in EAs, all associations found in the nonadjusted analysis disappeared when allergy was considered. This is not surprising given that associations identified in this study were enriched with genes involved in inflammation, autoimmunity, or allergic processes, such as the inflammatory gene PTGES, the HLA locus, the known atopic loci 5q22.1 and 5q31.1 (11, 12, 16, 42, 48) , or the established autoimmune susceptibility gene CLEC16A, which has been linked to asthma with hay fever in adults (15) .
This study adds to the understanding of the genetic architecture of asthma in EA and AA populations with four novel asthma risk loci identified, including one associated with nonallergic asthma, and reinforces the need to study populations of diverse ethnic background to identify both shared and unique genetic predictors that contribute to the observed heterogeneity across ethnic groups. Although further studies are needed to functionally validate the culprit genes at these loci, the biologic relevance of the candidate genes of interest suggests that novel therapies may be developed to more effectively treat the underlying causes of this common disease. n
